Lotrel medication
Pro Research Analysisby 
Searched over 200M research papers for "lotrel medication"
Efficacy and Benefits of Lotrel Medication in Hypertension Management
Introduction to Lotrel Medication
Lotrel is a combination medication consisting of amlodipine besylate, a calcium channel blocker, and benazepril hydrochloride, an angiotensin-converting enzyme (ACE) inhibitor. This combination is used primarily to treat high blood pressure (hypertension), particularly in patients with more severe forms of the condition.
Combination Therapy vs. Monotherapy in Hypertension
Superior Blood Pressure Reduction
Research consistently shows that Lotrel's combination therapy is more effective in reducing systolic blood pressure (SBP) compared to monotherapy with either amlodipine or benazepril alone. The SELECT (Systolic Evaluation of Lotrel Efficacy and Comparative Therapies) trial demonstrated that patients treated with the combination therapy experienced significantly greater reductions in mean 24-hour SBP and pulse pressure than those treated with either component alone . This finding supports the recommendation for combination therapy as a first-line treatment for stage 2 hypertension, as outlined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).
Improved Blood Pressure Control Rates
The SELECT study also found that a significantly higher percentage of patients achieved blood pressure control with the combination therapy compared to monotherapy. This suggests that Lotrel is not only more effective in lowering blood pressure but also in helping patients reach their target blood pressure levels.
Safety and Tolerability
Lower Incidence of Peripheral Edema
One of the notable advantages of Lotrel's combination therapy is its safety profile. The incidence of peripheral edema, a common side effect associated with amlodipine, was lower in patients receiving the combination therapy compared to those on amlodipine monotherapy. This indicates that the addition of benazepril may mitigate some of the adverse effects of amlodipine.
General Tolerability
Adverse event rates were low and similar across all treatment groups in the SELECT study, indicating that Lotrel is well tolerated by patients . This is crucial for long-term adherence to hypertension treatment regimens.
Impact on Left Ventricular Hypertrophy
Reduction in Left Ventricular Mass Index
Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular morbidity and mortality, often caused by hypertension. The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study found that Lotrel significantly reduced the left ventricular mass index in patients with high-risk hypertension over 52 weeks of treatment. This reduction was more pronounced in female patients, highlighting the potential gender-specific benefits of the medication.
Conclusion
Lotrel, a combination of amlodipine besylate and benazepril hydrochloride, offers superior efficacy in reducing systolic blood pressure and pulse pressure compared to monotherapy with either component. It also provides better blood pressure control rates and has a favorable safety profile with a lower incidence of peripheral edema. Additionally, Lotrel is effective in reducing left ventricular hypertrophy, particularly in female patients. These findings underscore the benefits of combination therapy in managing stage 2 hypertension and support its use as recommended by clinical guidelines.
Sources and full results
Most relevant research papers on this topic